{
    "organizations": [],
    "uuid": "76d189a4d9f49844114fd6c763a1ba37858acdec",
    "author": "Adam Clark",
    "url": "https://www.wsj.com/articles/takeda-mulls-bid-for-pharma-rival-shire-1522231040",
    "ord_in_thread": 0,
    "title": "Takeda Mulls Bid for Pharma Rival Shire",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Takeda Pharmaceutical Co. said it was weighing a bid for rival Shire PLC, a potential deal that would create a global drug giant worth nearly $90 billion and mark the latest move in an industry brimming with deal activity.\nShares of London-listed Shire, the maker of drugs such as Adderall, for attention deficit hyperactivity disorder, soared more than 20% after the disclosure, boosting its market value to £33.2 billion, or about $47 billion—higher than Takeda’s $42 billion value at the close of Tokyo trading Wednesday.\n... To Read the Full Story Subscribe Sign In",
    "published": "2018-03-28T14:42:00.000+03:00",
    "crawled": "2018-03-28T14:17:21.026+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "takeda",
        "pharmaceutical",
        "said",
        "weighing",
        "bid",
        "rival",
        "shire",
        "plc",
        "potential",
        "deal",
        "would",
        "create",
        "global",
        "drug",
        "giant",
        "worth",
        "nearly",
        "billion",
        "mark",
        "latest",
        "move",
        "industry",
        "brimming",
        "deal",
        "activity",
        "share",
        "shire",
        "maker",
        "drug",
        "adderall",
        "attention",
        "deficit",
        "hyperactivity",
        "disorder",
        "soared",
        "disclosure",
        "boosting",
        "market",
        "value",
        "billion",
        "takeda",
        "billion",
        "value",
        "close",
        "tokyo",
        "trading",
        "wednesday",
        "read",
        "full",
        "story",
        "subscribe",
        "sign"
    ]
}